Ir para o conteúdo principal

Altimmune (NYSE: ALT) — Perfil da empresa, notícias e dados financeiros

Logo de Altimmune
ALT Altimmune
Altimmune primary media
Perfil da empresa

Altimmune

Altimmune (NASDAQ:ALT) is a clinical-stage biopharmaceutical company focused on developing treatments that address critical needs in respiratory diseases and immune-modulating therapies. Their operations span the discovery, development, and commercialization of novel products to improve the lives of patients suffering from a range of conditions including obesity, liver diseases, and COVID-19. One of their flagship projects is a vaccine aimed at providing long-lasting protection against influenza, showcasing their commitment to tackling global health challenges. With a strategic approach to innovation and a dedicated team, Altimmune aims to advance its pipeline of promising candidates through the clinical stages, continually seeking to expand its impact on public health worldwide.

Resumo

Public USParticipação acionária
1997Ano de fundação
69Funcionários
Gaithersburg, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
Gaithersburg, US

Produtos e/ou serviços de Altimmune

  • HepTcell, a therapeutic vaccine candidate for the treatment of chronic hepatitis B.
  • AdCOVID, a single-dose intranasal vaccine candidate for COVID-19.
  • T-COVID, an intranasal immunomodulator treatment for early COVID-19.
  • ALT-801, a novel GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic steatohepatitis (NASH).
  • NasoShield, an anthrax vaccine candidate administered through a single intranasal dose.
  • NasoVAX, an intranasal influenza vaccine candidate designed to provide long-lasting protection.

equipe executiva do Altimmune

  • Jerome Benedict DursoChairman, CEO & President
  • M. Scot RobertsChief Scientific Officer
  • Christophe Arbet-EngelsChief Medical Officer
  • Gregory L. WeaverChief Financial Officer
  • Richard MenziusoVP, Global Controller & Principal Accounting Officer
  • Bertrand GeorgesChief Technology Officer
  • Luis SanayVice President of Investor Relations
  • Tony BlandinVice President of Quality & Compliance Management
  • Robin E. AbramsChief Legal Officer & Corporate Secretary
  • Raymond M. JordtChief Business Officer

Comunicados recentes

O que a Altimmune (ALT) comunicou ao mercado, do mais recente para o mais antigo.

  1. 4 | Altimmune, Inc.
  2. SCHEDULE 13G/A | Altimmune, Inc.
  3. 4 | Altimmune, Inc.
  4. 4 | Altimmune, Inc.
  5. 4 | Altimmune, Inc.
  6. 4 | Altimmune, Inc.
  7. 10-Q | Altimmune, Inc.
  8. 8-K | Altimmune, Inc.

Histórico de dividendos

Dividendos por ação pagos pela Altimmune, por ano fiscal.

Dividendos por ação da Altimmune por ano fiscal
Ano fiscalIntermediárioFinalEspecialTotal
FY2016—$875.9200—$875.9200

Principais indicadores financeiros

Resultados divulgados pela Altimmune, em USD.

Cap. de mercado
274,4 mi
Receita (TTM)
26 mil
P/L
—
LPA (diluído, TTM)
-0.7
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Altimmune
Fim do ano fiscalReceitaResultado operacionalLucro líquido
41 mil-94,5 mi-88,1 mi
20 mil-103,2 mi-95,1 mi
426 mil-95,9 mi-88,4 mi
-68 mil-87,7 mi-84,7 mi